Table.
Protection against omicron sublineages by outcome
| Country | Outcome | Primary variant | Subsequent variant | Protection (95% UI) | Weeks after infection | |
|---|---|---|---|---|---|---|
| Studies without information on time since infection | ||||||
| Chemaitelly et al (2022)33 | Qatar | Infection | Omicron BA.1 | Omicron BA.2 | 94·2 (89·2 to 96·9) | .. |
| Chemaitelly et al (2022)33 | Qatar | Infection | Omicron BA.2 | Omicron BA.1 | 80·9 (73·1 to 86·4) | .. |
| Altarawneh et al (2022)32 | Qatar | Infection | Ancestral | Omicron BA.4/BA.5 | 27·7 (19·3 to 35·2) | .. |
| Altarawneh et al (2022)32 | Qatar | Infection | Omicron BA.1 | Omicron BA.4/BA.5 | 78·0 (75·0 to 80·7) | .. |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 47·0 (44·0 to 50·0) | .. |
| Altarawneh et al (2022)35 | Qatar | Symptomatic | Ancestral | Omicron BA.2 | 46·1 (39·5 to 51·9) | .. |
| Altarawneh et al (2022)32 | Qatar | Symptomatic | Ancestral | Omicron BA.4/BA.5 | 35·5 (12·1 to 52·7) | .. |
| Altarawneh et al (2022)32 | Qatar | Symptomatic | Omicron BA.1 | Omicron BA.4/BA.5 | 76·2 (66·4 to 83·1) | .. |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 49·0 (45·0 to 52·0) | .. |
| Powell et al (2022)36 | UK | Symptomatic | Omicron BA.1 | Omicron BA.1 | 59·3 (46·7 to 69·0) | .. |
| Altarawneh et al (2022)35 | Qatar | Severe | Ancestral | Omicron BA.2 | 73·4 (0·2 to 92·9) | .. |
| Studies with information on time since infection | ||||||
| Carazo et al (2022)37 | Canada | Infection | Ancestral | Omicron BA.2 | 42·0 (−47·0 to 77·0) | 17 |
| Carazo et al (2022)37 | Canada | Infection | Ancestral | Omicron BA.2 | 39·0 (0 to 63·0) | 37 |
| Carazo et al (2022)37 | Canada | Infection | Ancestral | Omicron BA.2 | 42·0 (17·0 to 60·0) | 58 |
| Carazo et al (2022)37 | Canada | Infection | Omicron BA.1 | Omicron BA.2 | 82·0 (49·0 to 94·0) | 5 |
| Carazo et al (2022)37 | Canada | Infection | Omicron BA.1 | Omicron BA.2 | 76·0 (63·0 to 85·0) | 9 |
| Carazo et al (2022)37 | Canada | Infection | Omicron BA.1 | Omicron BA.2 | 70·0 (61·0 to 77·0) | 17 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 76·0 (68·0 to 82·0) | 6 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 56·0 (48·0 to 62·0) | 10 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 50·0 (43·0 to 56·0) | 15 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 57·0 (49·0 to 64·0) | 19 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 50·0 (36·0 to 61·0) | 23 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 53·0 (42·0 to 62·0) | 27 |
| Andeweg et al (2022)34 | Netherlands | Infection | Ancestral | Omicron BA.2 | 38·0 (34·0 to 43·0) | 32 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 76·0 (69·0 to 82·0) | 6 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 57·0 (49·0 to 63·0) | 10 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 50·0 (43·0 to 56·0) | 15 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 58·0 (50·0 to 66·0) | 19 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 55·0 (41·0 to 65·0) | 23 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 52·0 (40·0 to 62·0) | 27·5 |
| Andeweg et al (2022)34 | Netherlands | Symptomatic | Ancestral | Omicron BA.2 | 40·0 (35·0 to 44·0) | 32 |